Please assess the completion status of the following clinical trial:

Trial Title: Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device (LVAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* LVAD (HVAD, Heartware Inc., Framingham, MA, USA) implantation more than one month ago~* Stable renal function (clinical judgement)~* Age 18 years or older~* Ability to give informed consent~Exclusion Criteria:~* Severe chronic renal impairment (CL\<30)~* History of significant thromboembolic events~* Significant bleeding disorder~* HIV or Hepatitis C infection~* Heparin induced thrombocytopenia~* Known hypersensitivity to Dabigatran or Phenprocoumon

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- study medication (Type: EXPERIMENTAL): Dabigatran 110mg twice daily with normal renal function (glomerular filtration rate \>80 ml/min) Dabigatran 75mg twice daily with impaired renal function (glomerular filtration rate between 80 and 30 ml/min)
- control group (Type: ACTIVE_COMPARATOR): Phenprocoumon dosage according to INR

Based on this trial design, predict the completion outcome and termination type (if applicable).